Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity

American Journal of Cardiology

Volumn 90, Issue 8 SUPPL., 2002, Pages 30-47

  Kwiterovich Jr , Peter O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIDE; FAT; FATTY ACID; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; PROCOAGULANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 1; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ENDOTHELIUM LESION; FAMILIAL HYPERLIPEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID TRANSPORT; GENE EXPRESSION REGULATION; GENE FUNCTION; HEREDITARY HYPERTENSION; HEREDITY; HUMAN; HYDROLYSIS; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIVER LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037126377     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02749-2     Document Type: Article

References (176)

1. Wilson P.W., Castelli W.P., Kannel W.B. Coronary risk prediction in adults (The Framingham Study). Am J Cardiol. 59:1987;91G-94G.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2508-2509.
3. Grundy SM. Approach to lipoprotein management in 2001 national cholesterol guidelines. Am J Cardiol 2002;90(suppl):11i-21i.
4. Kwiterovich P.O. Jr. The effect of dietary fat, antioxidants and pro-oxidants on blood lipids and lipoproteins and atherosclerosis. J Am Diet Assoc. 97:(suppl):1997;S31-S41.
5. Kwiterovich P.O. Jr. State of the art update and review clinical trials of lipid-lowering agents . Am J Cardiol. 82:(suppl):1998;3U-17U.
6. Gotto AM Jr, Farmer JA. Lipid-lowering trials. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease, 6th ed. New York: WB Saunders, 2001;1066-1086.
7. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791.
8. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143.
9. Blake G.J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ Res. 89:2001;763-771.
10. Kwiterovich P.O. Jr. The metabolic pathways of HDL, LDL and triglycerides. A current review. Am J Cardiol. 86:(suppl 1):2000;5-10.
11. Haffner SM. Lipoprotein disorders associated with type 2 diabetes and insulin resistance. Am J Cardiol 2002;90(suppl):55i-61i.
12. Sniderman A.D., Scantlebury T., Cianflione K. Hypertriglyceridemic hyperapoB the unappreciated atherogenic dyslipidemia in type 2 diabetes . Ann Intern Med. 135:2001;447-459.
13. Mackey RH, Kuller LH, Matthews KA, Sutton-Tyrrell K, Evans RW, Holubkov R. Lipoprotein subclasses and coronary calcification in postmenopausal women from the Healthy Women Study. Am J Cardiol 2002;90(suppl):71i-76i.
14. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol 2002;90(suppl):77i-84i.
15. Otvos JD, Jeyarajh EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002;90(suppl):22i-29i.
16. Krauss R.M. Dietary and genetic effects on low-density lipoprotein heterogeneity. Ann Rev Nutr. 21:2001;283-295.
17. Millar J.S., Packard C.J. Heterogeneity of apolipoprotein B-100-containing lipoproteins what we have learnt from kinetic studies . Curr Opin Lipidol. 9:1998;197-202.
18. Demant T., Packard C. In vivo studies of VLDL metabolism and LDL heterogeneity. Eur Heart J. 19:(suppl H):1998;H7-H10.
19. Packard C., Caslake M., Shepherd J. The role of small, dense low-density lipoprotein (LDL) a new look . Int J Cardiol. 74:(suppl 1):2000;S17-S22.
20. Aouizerat B.E., Allayee H., Bodnar J., Krass K.L., Peltonen L., de Bruin T.W., Rotter J.I., Lusis A.J. Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol. 10:1999;113-122.
21. Sniderman AD. How and when to use apoB in clinical practice. Am J Cardiol 2002;90(suppl):48i-54i.
22. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol 2002;90(suppl):62i-70i.
23. Sniderman A., Shapiro S., Marpole D., Malcolm I., Skinner B., Teng B., Kwiterovich P.O. Jr. The association of coronary atherosclerosis and hyperapobetalipoproteinemia (increased protein but normal cholesterol content in human plasma low density lipoprotein). Proc Natl Acad Sci U S A. 77:1980;604-608.
24. Sniderman A., Wolfson C., Teng B., Franklin F., Bachorik P.S., Kwiterovich P.O. Jr. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med. 97:1982;833-839.
25. Teng B., Thompson G.R., Sniderman A.D., Forte T.M., Krause R.M., Kwiterovich P.O. Jr. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia and familial hypercholesterolemia. Proc Natl Acad Sci U S A. 80:1983;662-666.
26. Kwiterovich P.O. Jr, Coresh J., Derby C., Smith H.H., Bachorik P.S., Pearson T.A. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 9:1992;1015-1021.
27. Kwiterovich P.O. Jr, Coresh J., Bachorik P.S. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged ≤50 years) and women (≤60 years) with coronary artery disease. Am J Cardiol. 15:1993;631-639.
28. Genest J.J. Jr, Martin-Munley S.S., McNamara J.R., Ordovas J.M., Jenner J., Myers R.H., Silberman S.R., Wilson P.W., Salem D.N., Schaefer E.J. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 85:1992;2025-2033.
29. Coresh J., Kwiterovich P.O. Jr, Smith H.H., Bachorik P.S. Association of plasma triglyceride concentration and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 34:1993;1687-1697.
30. Hokanson J.E., Krauss R.M., Albers J.J., Austin M.A., Brunzell J.D. LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 15:1995;452-459.
31. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein patterns and risk of myocardial infarction. JAMA. 260:1998;1917-1921.
32. Hunt S.C., Wu L.L., Hopkins P.N., Stults B.M., Kuida H., Ramirez M.E., Lalouel J.M., Williams R.R. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis. 9:1989;335-344.
33. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 92:1993;141-145.
34. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 52:1973;1544-1568.
35. Austin M.A., Brunzell J.D., Fitch W.L., Krauss R.M. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis. 10:1990;520-530.
36. Sniderman A.D., Castro Cabezas M., Ribalta J., Carmena R., de Bruin T.W.A., de Graaf J., Erkelens D.W., Humphries S.E., Masana L., Real J.T., Talmud P.J., Taskinen M.R. A proposal to redefine familial combined hyperlipidemia. Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation. Eur J Clin Invest. 32:2002;71-73.
37. Demacker P.N., Veerkamp M.J., Bredie S.J., Marcovina S., de Graaf J., Stalenhoef A.F. Comparison of the measurement of lipids and lipoproteins versus assay for apolipoprotein B for estimation of coronary heart disease risk a study in familial combined hyperlipidemia . Atherosclerosis. 153:2000;483-490.
38. Veerkamp M.J., de Graft J., Bredie S.J., Henricks J.C., Demacker P.N., Stalenhoef A.F. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families results of a 5-year follow-up study . Arterioscler Thromb Vasc Biol. 22:2002;274-282.
39. Krauss RM, Blanche PJ. Detection and quantitation of LDL subfractions. Curr Opin Lipidol. 3:1992;377-383.
40. Campos H., Blijlevens E., McNamara J.R., Ordovas J.M., Posner B.M., Wilson P.W., Castelli W.P., Schaefer E.J. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 12:1992;1410-1419.
41. Kulkarni K.R., Garber D.W., Marcovina S.M., Segrest J.P. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res. 35:1994;159-168.
42. Yip J., Facchini F.S., Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab. 83:1998;2773-2776.
43. Howard B., O'Leary D.H., Zaccaro D., Haffner S., Rewers M., Hamman R., Selby J.V., Saad M.F., Savage P., Bergman R. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 93:1996;1809-1817.
44. Reaven G.M. Role of insulin resistance in human disease (syndrome X) an expanded definition . Annu Rev Med. 44:1993;121-131.
45. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
46. Zavaroni I., Bonini L., Gasparini P., Barilli A.L., Zuccarelli A., Dall'Aglio E., Delsignore R., Reaven G.M. Hyperinsulinemia in a normal population as a predictor of non-insulin dependent diabetes, hypertension, and coronary heart disease the Barilla factory revisited . Metabolism. 48:1999;989-994.
47. Vaisanen S., Baumstark M.W., Penittila I., Bouchard C., Halonen P., Rankinen T., Berg A., Rauramaa R. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb Haemost. 78:1997;1495-1499.
48. Purnell J.G., Kahn S.E., Schwartz R.S., Brunzell J.D. Relationship of insulin sensitivity and apoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 21:2001;567-579.
49. Keulin E.T., Voors-Pette C., de Bruin T.W. Familial dyslipidemic hypertension syndrome familial combined hyperlipidemia, and the role of abdominal fat mass . Am J Hypertens. 14:2001;357-363.
50. Festa A., D'Agostino R. Jr, Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 102:2000;42-47.
51. Facchini F.S., Humphreys M.H., DoNascimento C.A., Abbasi F., Reaven G.M. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr. 72:2000;766-769.
52. Chen N.G., Azhar S., Abbasi F., Carantoni M., Reaven G.M. The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis. 152:2000;203-208.
53. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 286:2001;327-334.
54. Sniderman A.D., Ribalta J., Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases? Nutr Metab Cardiovasc Dis. 11:2001;259-273.
55. Teng B., Sniderman A.D., Soutar A.K., Thompson G.R. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest. 77:1986;663-672.
56. Sniderman A.D., Maslowska M., Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. Curr Opin Lipidol. 11:2000;291-296.
57. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest. 106:2000;453-458.
58. Abbasi F., McLaughlin T., Lamendola C., Reaven G.M. Insulin regulation of plasma free fatty acid concentrations is abnormal in healthy subjects with muscle insulin resistance. Metabolism. 49:2000;151-154.
59. Pei D., Chen Y.D., Hollenbeck C.B., Bhargava R., Reaven G.M. Relationship between insulin-mediated glucose disposal by muscle and adipose tissue lipolysis in healthy volunteers. J Clin Endocrinol Metab. 80:1995;3368-3372.
60. McKeigue P.M., Laws A., Chen Y.D., Marmot M.G., Reaven G.M. Relation of plasma triglyceride and apoB levels to insulin-mediated suppression of nonesterified fatty acids. Possible explanation for sex differences in lipoprotein pattern. Arterioscler Thromb. 13:1993;1187-1192.
61. Castro Cabezas M., de Bruin T.W., de Valk H.W., Shoulders C.C., Jansen H., Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 92:1993;160-168.
62. 2 heterogeneity. in Proceedings of the Workshop on Lipoprotein Heterogeneity. Rockville, MD: Agency for Healthcare Policy and Research, U.S. Dept of Health and Human Services, 1987:293-304. NIH Publication No. 87-2646.
63. Kwiterovich PO, Motevalli M. HyperapoB - an update. Atherosclerosis X: Proceedings of the 10th International Symposium on Atherosclerosis;Montreal; October 9-14, 1994. Amsterdam: Elsevier Science. 1995;966-971.
64. Motevalli M., Goldschmidt-Clermont P.J., Virgil D.G., Kwiterovich P.O. Jr. Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapoB subjects. J Biol Chem. 272:1997;24703-24709.
65. Genest J., Sniderman A., Cianflone K., Teng B., Wacholder S., Marcel Y., Kwiterovich P.O. Jr. Hyperapolipoproteinemia: plasma lipoprotein responses to oral fat load. Arteriosclerosis. 6:1986;297-304.
66. Cabezas M.C., de Bruin T.W., Jansen H., Kock L.A., Kortlandt W., Erkelens D.W. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb. 13:1993;804-814.
67. Jeppesen J., Hollenbeck C.B., Zhou M.-Y., Coulston A.M., Jones C., Chen Y.-D., Reaven G.M. Relation between insulin resistance, hyperinsulinemia, post-heparin plasma lipoprotein lipase activity and postprandial lipemia. Arterioscler Thromb Vasc Biol. 15:1995;320-324.
68. Sniderman A.D. Postprandial hypertriglyceridemia(s) time to enlarge our pathophysiologic perspective . Eur J Clin Invest. 30:2000;935-937.
69. Meijssen S., Castro Cabezas M., Twickler T.B., Jansen H., Erkelens D.W. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res. 41:2000;1096-1102.
70. Reynisdottir S., Eriksson M., Angelin B., Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest. 95:1995;2161-2169.
71. Aitman T.J., Godsland I.F., Farren B. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 17:1997;748-754.
72. Nevin D.N., Brunzell J.D., Deeb S.S. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler Thromb. 14:1994;869-873.
73. Yang W.S., Nevin D.N., Iwasaki L., Peng R., Brown B.G., Brunzell J.D., Deeb S.S. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res. 37:1996;2627-2637.
74. Castro Cabezas M., De Bruin T.W.A., Kock L.A.W. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism. 42:1993;503-508.
75. Juo S.H., Beaty T.H., Kwiterovich P.O. Jr. Etiologic heterogeneity of hyperapobetalipoproteinemia (hyperapoB). Results from segregation analysis in families with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 11:1997;2729-2736.
76. Jarvik G.P., Beaty T.H., Gallagher P.R., Coates P.M., Cortner J.A. Genotype at a major locus with large effects on apolipoprotein B levels predicts familial combined hyperlipidemia. Genet Epidemiol. 10:1993;257-270.
77. Jarvik G.P., Brunzell J.D., Austin M.A., Krauss R.M., Motulsky A.G., Wijsman E. Genetic predictors of FCHL in four large pedigrees influence of apoB level major locus predicted genotype and LDL subclass phenotype . Arterioscler Thromb. 14:1994;1687-1694.
78. Bredie S.J., van Drongelen J., Kiemeney L.A., Demacher P.N., Beaty T.H., Stalenhoef A.F. Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 17:1997;834-840.
79. Juo S.H., Bredie S.J., Kiemeney L.A., Demacjer P.N., Stalenhoef A.F. A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. Am J Hum Genet. 63:1998;586-594.
80. Kwiterovich P.O. Jr. Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol. 4:1993;133-143.
81. Austin M.A., King M.C., Vranizan K.M., Newman B., Krauss R.M. Inheritance of low-density lipoprotein subclass patterns results of complex segregation analysis . Am J Hum Genet. 43:1988;838-846.
82. Siegel R.D., Cupples A., Schaefer E.J., Wilson P.W. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 45:1996;1267-1272.
83. Facchini F., Chen Y.D., Clinkingbeard C., Jeppesen J., Reaven G.M. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens. 5:1992;694-699.
84. Zavaroni I., Mazza S., Luchetti L., Buonanno G., Bonati P.A., Bergonzani M., Passeri M., Reaven G.M. High plasma insulin and triglyceride concentrations and blood pressure in offspring of people with impaired glucose tolerance. Diabet Med. 7:1990;494-498.
85. Ericksson J., Franssila-Kallunki A., Ekstrand A., Saloranta C., Widen E., Schalin C., Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 69:1989;343-347.
86. Ho L.T., Chang Z.Y., Wang J.T., Li S.H., Liu Y.F., Chen Y.-D.I., Reaven G.M. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med. 7:1990;31-34.
87. Xiang A.H., Azen S.P., Raffel C.J., Tan S., Cheng L.S., Diaz J., Toscano E., Henderson P.C., Hodis H.N., Hsueh W.A., Rotter J.L. Evidence for joint genetic control of insulin sensitivity and systolic blood pressure in Hispanic families with hypertensive probands. Circulation. 103:2001;78-83.
88. Godfrey K.M., Barker D.J.P. Fetal nutrition and adult disease. Am J Clin Nutr. 71:(suppl):2000;1344S-1352S.
89. Ijzerman R.G., Stehouwer C.D., Boomsma D.I. Evidence for genetic factors explaining the birth weight-blood pressure relation analysis in twins . Hypertension. 36:2000;1008-1012.
90. Ijzerman R.G., Stehouwer C.D., van Weissenbruch M.M., De Geus E.J., Boomsma D.I. Evidence for genetic factors explaining the association between birth weight and LDL cholesterol, and possible intrauterine factors influencing the association between birth weight and HDL cholesterol analysis in twins . J Clin Endocrinol Metab. 86:2001;5479-5484.
91. Jaquish C.E., Mitchell B.D., Kammerer C.M., Atwood L.D., Bradshaw B.S., MacCluer J.W. The inverse relationship between birth weight and adult blood pressure may be mediated by common genes influencing both birth and adult weight evidence from the San Antonio Family Heart Study [abstract] . Circulation. 94:1996;I-213.
92. Hattersley A.T., Tooke J.E. The fetal insulin hypothesis an alternative explanation of the association of low birth weight with diabetes and vascular disease . Lancet. 353:1999;1789-1792.
93. Coresh J., Beaty T.H., Kwiterovich P.O. Jr, Antonarakis S. Pedigree and sib pair linkage analysis suggest the apoB gene is not the major gene influencing plasma apoB. Am J Hum Genet. 50:1992;1038-1045.
94. Austin MA, Wijsman E, Guo SW, Krauss RM, Brunzell JD, Deeb S. Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia. Genet Epidemiol 1991;8:287-297.
95. LaBelle M., Austin M.A., Rubin E., Krauss R.M. Linkage analysis of low-density lipoprotein subclass phenotypes and the apolipoprotein B gene. Genet Epidemiol. 8:1991;269-275.
96. Austin MA, Talmud PJ, Luong LA, Haddad L, Day IN, Newman B, Edwards KL, Krauss RM, Humphries SE. Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins. Am J Hum Genet 1998;62:406-419.
97. Juo S.H., Han Z., Smith J.D., Colangelo L., Liu K. Common polymorphism in promotor of microsomal triglyceride transfer protein gene influences cholesterol, apoB, and triglyceride levels in young African American men results from the coronary artery risk development in young adults (CARDIA) study . Arterioscler Thromb Vasc Biol. 20:2000;1316-1322.
98. Aouizerat B.E., Allayee H., Cantor R.M., Dallinga-Thie G.M., Lanning C.D., de Bruin T.W., Lusis A.J., Rotter J.I. Linkage of a candidate gene locus to familial combined hyperlipidemia lecithin:cholesterol acyltransferase on 16q . Arterioscler Thromb Vasc Biol. 19:1999;2730-2736.
99. Hokanson J.E., Brunzell J.D., Jarvik G.P., Wijsman E.M., Austin M.A. Linkage of low-density lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency. Am J Hum Genet. 64:1999;608-618.
100. Dallinga-Thie G.M., van Linde-Sibenius Trip M., Rotter J.I., Cantor R.M., Bu X., Lusis A.J., de Bruin T.W. Complex genetic contribution of the ApoAI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J Clin Invest. 99:1997;953-961.
101. Allayee H., Aouizerat B.E., Cantor R.M., Dallinga-Thie G.M., Krauss R.M., Lanning C.D., Rotter J.I., Lusis A.J., de Bruin T.W. Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. Am J Hum Genet. 63:1998;577-585.
102. Talmud P.J., Edwards K.L., Turner C.M., Newman B., Palmen J.M., Humphries S.E., Austin M.A. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size use of a novel tetranucleotide repeat within the CETP promoter . Circulation. 101:2000;2461-2466.
103. Allayee H., Dominguez K.M., Aouizerat B.E., Krauss R.M., Rotter J.I., Lu J., Cantor R.M., de Bruin T.W., Lusis A.J. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J Lipid Res. 41:2000;245-252.
104. Auwerx J.H., Marzetta C.A., Hokanson J.E., Brunzell J.D. Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis. 9:1989;319-325.
105. Qiu S., Bergeron N., Kotite L., Krauss R.M., Bensadoun A., Havel R.J. Metabolism of lipoproteins containing apolipoprotein B in hepatic lipase-deficient mice. J Lipid Res. 39:1998;1661-1668.
106. Zambon A., Deeb S.S., Brown B.G., Hokanson J.E., Brunzell J.D. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation. 103:2001;792-798.
107. 4019→Trp), a new apo B100 variant in a family with premature atherosclerosis and hyperapobetalipoproteinemia. JAMA. 262:1989;1980-1988.
108. Galeano N.F., Al-Haideri M., Keyserman F., Rumsey S.C., Deckelbaum R.J. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites a potential mechanism for increased atherogenicity . J Lipid Res. 39:1998;1263-1273.
109. Pajukanta P., Nuotio I., Terwilliger J.D., Porkka K.V., Ylitalo K., Pihlajamaki J., Suomalainen A.J., Syvanen A.C., Lehtimaki T., Viikari J.S. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet. 18:1998;369-373.
110. Pei W., Baron H., Muller-Myhsok B., Knoblauch H., Al-Yahyaee S.A., Hui R., Wu X., Liu L., Busjahn A., Luft F.C., Schuster H. Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families. Clin Genet. 57:2000;29-34.
111. Coon H., Myers R.H., Borecki I.B., Arnett D.K., Hunt S.C., Province M.A., Djousse L., Leppert M.F. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus the NHLBI Family Heart Study . Arterioscler Thromb Vasc Biol. 20:2000;2275-2280.
112. Castellani L.W., Weinreb A., Bodnar J., Goto A.M., Doolittle M., Mehrabian M., Demant P., Lusis A.J. Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. Nat Genet. 18:1998;374-377.
113. Bodnar J.S., Chatterjee A., Castellani L.W., Ross D.A., Ohmen J., Cavalcoli J., Wu C., Dains K.M., Catanese J., Chu M. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet. 30:2002;110-116.
114. Aouizerat B.E., Allayee H., Cantor R.M., Davis R.C., Lanning C.D., Wen P.Z., Dallinga-Thie G.M., de Bruin T.W., Rotter J.I., Lusis A.J. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet. 65:1999;397-412.
115. Allayee H., Krass K.L., Pajukanta P., Cantor R.M., van der Kallen C.J., Mar R., Rotter J.I., de Bruin T.W., Peltonen L., Lusis A.J. Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ Res. 90:2002;926-931.
116. Pajukanta P., Terwilliger J.D., Perola M., Hiekkalinna T., Nuotio I., Ellonen P., Parkkonen M., Hartiala J., Ylitalo K., Pihlajamaki J. Genome wide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J Hum Genet. 64:1999;1453-1463.
117. Geurts J.M., Janssen R.G., van Greevenbroek M.M., van der Kallen C.J., Cantor R.M., Bu X., Aouizerat B.E., Allayee H., Rotter J.I., de Bruin T.W. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet. 9:2000;2067-2074.
118. van Greevenbroek M.M., van der Kallen C.J., Geurts J.M., Janssen R.G., Buurman W.A., de Bruin T.W. Soluble receptors for tumor necrosis factor-alpha (TNF-R p55 and TNF-R p75) in familial combined hyperlipidemia. Atherosclerosis. 153:2000;1-8.
119. Mitchell B.D., Cole S.A., Hsueh W.-C., Comuzzie A.G., Biangero J., MacCluer J.W., Hixson J.E. Linkage of serum insulin concentrations to chromosome 3p in Mexican Americans. Diabetes. 49:2000;513-516.
120. Terauchi Y., Kubota N., Tamemoto H., Sakura H., Nagai R., Akanuma Y., Kimura S., Kadowaki T. Insulin effect during embryogenesis determines fetal growth. A possible molecular link between birth weight and susceptibility to type 2 diabetes. Diabetes. 49:2000;82-86.
121. Tamenoto H., Kadowaki T., Tobe K., Yagi T., Sakura H., Hayakawa T., Terauchi Y., Ueki K., Kaburagi Y., Satoh S. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature. 372:1994;182-186.
122. Hegele R.A. Premature atherosclerosis associated with monogenic insulin resistance. Circulation. 103:2001;222-225.
123. Burks D.J., White M.F. IRS proteins and beta-cell function. Diabetes. 50:(suppl 1):2001;S140-S145.
124. Zhang J., Ou J., Bashmakov Y, Horton J.D., Brown M.S., Goldstein J.S. Insulin inhibits transcription of IRS-2 gene in rat liver through an insulin response element (IRE) that resembles IREs of other insulin-repressed genes. Proc Natl Acad Sci U S A. 98:2001;3756-3761.
125. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs) nuclear receptors at the crossroads between lipid metabolism and inflammation . Inflamm Res. 49:2000;497-505.
126. Baier L.J., Permana P.A., Yang X., Pratley R.E., Hanson R.L., Shen G.Q., Mott D., Knowler W.C., Cox N.J., Horikawa Y. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest. 106:2000;819-821.
127. Aitman T.J., Glazier A.M., Wallace C.A., Cooper L.D., Norsworthy P.J., Wahid F.N., Al-Majali K.M., Trembling P.M., Mann C.J., Shoulders C.C., et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 21:1999;76-83.
128. Pravenec M., Zidek V., Simakova M., Kren V., Krenova D., Horky K., Jachymova M., Mikova B., Kazdova L., Aitman T.J. Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J Clin Invest. 103:1999;1651-1657.
129. Pravenec M., Landa V., Zidek V., Musilova A., Kren V., Kazdova L., Aitman T.J., Glazier A.M., Ibrahimi A., Abumrad N.A. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet. 27:2001;156-158.
130. Glazier A.M., Scott J., Aitman T.J. Molecular basis of the Cd36 chromosomal deletion underlying SHR defects in insulin action and fatty acid metabolism. Mamm Genome. 13:2002;108-113.
131. Febbraio M., Abumrad N.A., Hajjar D.P., Sharma K., Cheng W., Pearce S.F., Silverstein R.L. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 274:1999;19055-19062.
132. Galeano N.F., Milne R., Marcel Y.L., Walsh M.T., Levy E., Ngu'yen T.D., Gleeson A., Arad Y., Witte L., al-Haideri M., et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein LDL is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem. 7:1994;511-519.
133. Teng B., Sniderman A.D., Krauss R.M., Kwiterovich P.O. Jr, Milne R.W., Marcel Y.L. Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses. J Biol Chem. 260:1985;5067-5072.
134. Chen G.C., Liu W., Duchateau P., Allaart J., Hamilton R.L., Mendel C.M., Lau K., Hardman D.A., Frost P.H., Malloy M.J., et al. Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects. J Biol Chem. 269:1994;29121-29128.
135. de Graaf J., Hak-Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 11:1991;298-306.
136. Dejager S., Bruckert E., Chapman M.J. Dense low density lipoprotein subspecies with subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 34:1993;295-308.
137. Tan K.C., Ai V.H., Chow W.S., Chau M.T., Leong L., Lam K.S. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilatation in patients with type 2 diabetes. J Clin Endocrinol Metab. 84:1999;3212-3216.
138. Goulinet S., Chapman M.J. Plasma LDL and HDL subspecies are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol. 17:1997;786-796.
139. Tribble D.L., Rizzo M., Chair A., Lewis D.M., Blanche P.J., Krauss R.M. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med. 110:2001;103-110.
140. Nordestgaard B.G., Zilversmit D.B. Comparison of arterial intimal clearances of LDL from diabetic and nondiabetic cholesterol-fed rabbits. Differences in intimal clearance explained by size differences. Arteriosclerosis. 9:1989;176-183.
141. Björnheden T., Babyi A., Bondjers G., Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 123:1996;43-56.
142. Hurt-Camejo E., Camejo G., Rosengren B., Lopez F., Wiklund O., Bondjers G. Differential uptake of proteoglycan-selected subfractions of low
143. Anber V., Griffin B.A., McConnell M., Packard C.J., Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 124:1996;261-271.
144. Sattar N., Petrie J.R., Jaap A.J. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis. 138:1998;229-235.
145. Festa A., D'Agostino R. Jr, Mykkänen L., Tracy R., Howard B.V., Haffner S.M. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 19:1999;605-610.
146. Weisser B., Locher R., de Graaf J., Moser R., Sachinidis A., Vetter W. Low density lipoprotein subfractions increase thromboxane formation in endothelial cells. Biochem Biophys Res Commun. 192:1993;1245-1250.
147. Weisser B., Locher R., de Graaf J., Vetter W. Low density lipoprotein subfractions and [Ca2+] in vascular smooth muscle cells. Circ Res. 73:1993;118-124.
148. Veniant M.M., Withycombe S., Young S.G. Lipoprotein size and atherosclerosis susceptibility in ApoE(-/-) and LDLr(-/-) mice. Arterioscler Thromb Vasc Biol. 21:2001;1567-1570.
149. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276:1996;875-878.
150. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
151. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions the Atherosclerosis Risk in Communities (ARIC) Study . Circulation. 104:2001;1108-1113.
152. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study . Lancet. 358:2001;2026-2033.
153. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 95:1997;69-75.
154. Lamarche B., Tchernof A., Mauriege P., Cantin B., Dagenais G.R., Lupien P.J., Despres J.P. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 279:1998;1955-1961.
155. Lamarche B., St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Despres J.P. A prospective, population based study of low density lipoprotein particle size as risk factor for ischemic heart disease in men. Can J Cardiol. 17:2001;859-865.
156. St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Bernard P.M., Despres J.P., Lamarche B. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 104:2001;2295-2299.
157. Skoglund-Andersson C., Tang R., Bond M.G., de Faire U., Hamsten A., Karpe F. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol. 19:1999;2422-2430.
158. Hulthe J., Bokemark L., Wikstrand J., Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis the Atherosclerosis and Insulin Resistance (AIR) study . Arterioscler Thromb Vasc Biol. 20:2000;2140-2147.
159. Liu M.L., Ylitalo K., Nuotio I., Salonen R., Salonen J.T., Taskinen M.R. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke. 33:2002;1255-1260.
160. Krauss R.M. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J. 113:1987;578-582.
161. Watts G.F., Mandalia S., Brunt J.N., Slavin B.M., Coltart D.J., Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 42:1993;1461-1467.
162. Mack W.J., Krauss R.M., Hodis H.N. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 16:1996;697-704.
163. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 94:1996;2146-2153.
164. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression hepatic lipase-mediated changes in LDL density . Circulation. 99:1999;1959-1964.
165. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
166. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
167. Campos H., Moye L.A., Glasser S.P., Stampfer M.J., Sacks F.M. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 286:2001;1468-1474.
168. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
169. Brown B.G., Brockenbrough A., Zhao X.-Q., Dowdy A.A., Monick E.A., Huss-Frechette E.E., Poulin D.C., Roca A.L. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a ten-year Familial Atherosclerosis Treatment Study (FATS) follow up [abstract]. Circulation. 98:1998;I-635.
170. Guerin M., Lassel T.S., Le Groff W., Farnier M., Chapman M.J. Action of atorvastatin in combined hyperlipidemia preferential reduction of cholesteryl ester transfer from HDL to VLDL particles . Arterioscler Thromb Vasc Biol. 20:2000;189-197.
171. Pontrelli L., Parris W., Adeli K., Cheung R.C. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 51:2002;334-342.
172. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2:2000;36-46.
173. Chapman M.J., Guerin M., Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 19:(suppl A):1998;A24-A30.
174. Milosavljevic D., Griglio S., Le Naour G., Chapman M.J. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia consequences for lipid accumulation in human monocytes-derived macrophages . Atherosclerosis. 155:2001;251-260.
175. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., Toth P.D., Favrot L.K., Kerzner B., Nash S.D. Long term safety and efficacy of a new once-daily niacin/lovastatin formulation in patients with dyslipidemia. Am J Cardiol. 89:2002;672-678.
176. Yoshida H., Ishikawa T., Ayaori M., Shige H., Ito T., Susukawa M., Nakamura H. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein a randomized, double-blind, placebo-controlled study . Atherosclerosis. 139:1998;179-187.